Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Mohamad Moussa, Athanasios Papatsoris, Despoina Sryropoulou, Mohamed Abou Chakra, Athanasios Dellis & Lazaros Tzelves. (2021) A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opinion on Pharmacotherapy 22:13, pages 1685-1728.
Read now
Read now
Javier Garcia Perlaza, Rima Aziziyeh, Anna Zhou, Vitor De Sousa Barbosa, Jenny Amaya, Joaquin Caporale, Monica Elena Alva, Juan Forero, Straus Tanaka, Gaurav Suri & David Garcia. (2021) The burden of skeletal-related events in four Latin American countries: Argentina, Brazil, Colombia, and Mexico. Journal of Medical Economics 24:1, pages 983-992.
Read now
Read now
Alison Stopeck, Adam Brufsky, Lisa Kennedy, Sumi Bhatta, Debajyoti Bhowmik, Jacqueline Buchanan, Nicolas Despiegel & Guy Hechmati. (2020) Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics 23:1, pages 37-47.
Read now
Read now
Evangelos Terpos, Aurelien Jamotte, Alexandra Christodoulopoulou, Marco Campioni, Debajyoti Bhowmik, Lisa Kennedy & Wolfgang Willenbacher. (2019) A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. Journal of Medical Economics 22:8, pages 766-776.
Read now
Read now
Articles from other publishers (5)
Conor McCloskey, María Toboso Ortega, Sunita Nair, Maria João Garcia & Federico Manevy. (2022) A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. PharmacoEconomics - Open 7:1, pages 3-36.
Crossref
Crossref
Michelle R. Sproat, Bradley Burton, Catherine Burdalski, Timothy Porter, Celia Proctor, Michael Goldenhorn, Kofi Andoh & Steven Gilmore. (2021) Evaluation of denosumab in adult oncology patients for the prevention of skeletal related events across a large academic health system. Journal of Oncology Pharmacy Practice, pages 107815522110525.
Crossref
Crossref
Deepak Dabkara. (2021) Cancer Treatment–Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review. Indian Journal of Medical and Paediatric Oncology 42:03, pages 240-246.
Crossref
Crossref
Roger von Moos, Luis Costa, Eva Gonzalez-Suarez, Evangelos Terpos, Daniela Niepel & Jean–Jacques Body. (2019) Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treatment Reviews 76, pages 57-67.
Crossref
Crossref
Lisa Kennedy, Sumita Bhatta, Guy Hechmati & Jacqueline Buchanan. (2018) Response to Cost-Effectiveness Analysis of Zoledronic Acid Once Per Month, Zoledronic Acid Once Every 3 Months, and Denosumab Once Per Month in Women With Breast Cancer and Skeletal Metastases. Journal of Clinical Oncology 36:10, pages 1051-1051.
Crossref
Crossref